共 56 条
[1]
Bhamidimarri KR(2018)Electronic address eee, European Association for the Study of the L: EASL recommendations on treatment of hepatitis C 2018 J Hepatol 69 461-511
[2]
Czul F(2015)Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease J Hepatol 63 763-765
[3]
Peyton A(2016)Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C J Hepatol 65 40-47
[4]
Levy C(2018)Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis Aliment Pharmacol Ther 47 526-532
[5]
Hernandez M(2016)Identification of Drug-Drug interactions in vitro: a case study evaluating the effects of Sofosbuvir and amiodarone on hiPSC-derived cardiomyocytes Toxicol Sci 154 174-182
[6]
Jeffers L(2016)Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in Guinea pigs and rhesus monkeys Hepatology 64 1430-1441
[7]
Roth D(2016)Harvoni (Ledipasvir with Sofosbuvir)-induced renal injury Am J Gastroenterol 111 148-149
[8]
Schiff E(2017)Acute interstitial nephritis associated with Sofosbuvir and Daclatasvir ACG Case Rep J 4 e84-undefined
[9]
O'Brien C(undefined)undefined undefined undefined undefined-undefined
[10]
Martin P(undefined)undefined undefined undefined undefined-undefined